U.S. Non-Invasive Cancer Diagnostics Market (2026 - 2033) Size, Share, & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology, By Indication, By End User, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Product
                        1.2.2. Technology
                        1.2.3. Indication
                        1.2.4. End User
                        1.2.5. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Non-Invasive Cancer Diagnostic Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                        3.2.2. Market restraint analysis
                    3.3. U.S. Non-Invasive Cancer Diagnostic Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrants
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
                    3.4. U.S. Non-Invasive Cancer Diagnostic Market: Pipeline Analysis
Chapter 4. U.S. Non-Invasive Cancer Diagnostic Market: Product Estimates & Trend Analysis
                    4.1. Product Segment Dashboard
                    4.2. U.S. Non-Invasive Cancer Diagnostic Market: Product Movement Analysis
                    4.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
                    4.4. Instruments
                        4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.2. Pathology-based Instruments
                            4.4.2.1. Pathology-based Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.2.2. Polymerase Chain Reaction (PCR) Instruments
                                4.4.2.2.1. Polymerase Chain Reaction (PCR) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.2.3. Next-generation Sequencing (NGS) Instruments
                                4.4.2.3.1. Next-generation Sequencing (NGS) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.2.4. Microarrays
                                4.4.2.4.1. Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.3. Imaging Instruments
                            4.4.3.1. Imaging Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.3.2. Magnetic Resonance Imaging (MRI)
                                4.4.3.2.1. Magnetic Resonance Imaging (MRI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.3.3. Computed Tomography (CT)
                                4.4.3.3.1. Computed Tomography (CT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.3.4. Positron Emission Tomography (PET)
                                4.4.3.4.1. Positron Emission Tomography (PET) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.3.5. Mammography
                                4.4.3.5.1. Mammography Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.4.3.6. Others (Ultrasound, etc.)
                                4.4.3.6.1. Others (Ultrasound, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Consumables
                        4.5.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Kits & Reagents
                        4.6.1. Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Non-Invasive Cancer Diagnostic Market: Technology Estimates & Trend Analysis
                    5.1. Technology Segment Dashboard
                    5.2. U.S. Non-Invasive Cancer Diagnostic Market: Technology Movement Analysis
                    5.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
                    5.4. Imaging
                        5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    5.5. Liquid Biopsy
                        5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    5.6. Immunoassay
                        5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. Non-Invasive Cancer Diagnostic Market: Indication Business Analysis
                    6.1. Indication Segment Dashboard
                    6.2. U.S. Non-Invasive Cancer Diagnostic Market: Indication Movement Analysis
                    6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
                    6.4. Lung Cancer
                        6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Breast Cancer
                        6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.6. Colorectal Cancer
                        6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.7. Prostate Cancer
                        6.7.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.8. Blood Cancer
                        6.8.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.9. Liver Cancer
                        6.9.1. Liver Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.10. Cervical Cancer
                        6.10.1. Cervical Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.11. Skin Cancer
                        6.11.1. Skin Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.12. Others (Thyroid Cancer, etc.)
                        6.12.1. Others (Thyroid Cancer, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Non-Invasive Cancer Diagnostic Market: End User Business Analysis
                    7.1. End User Segment Dashboard
                    7.2. U.S. Non-Invasive Cancer Diagnostic Market: End User Movement Analysis
                    7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
                    7.4. Hospitals
                        7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Diagnostic Laboratories
                        7.5.1. Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Others (Academic & Research Institutes, etc.)
                        7.6.1. Others (Academic & Research Institutes, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company/Competition Categorization
                    8.3. Vendor Landscape
                        8.3.1. Key company heat map analysis, 2025
                    8.4. Company Profiles
                        8.4.1. Abbott Laboratories
                            8.4.1.1. Company overview
                            8.4.1.2. Financial performance
                            8.4.1.3. Product benchmarking
                            8.4.1.4. Strategic initiatives
                        8.4.2. GE Healthcare
                            8.4.2.1. Company overview
                            8.4.2.2. Financial performance
                            8.4.2.3. Service benchmarking
                            8.4.2.4. Strategic initiatives
                        8.4.3. Siemens Healthineers AG
                            8.4.3.1. Company overview
                            8.4.3.2. Financial performance
                            8.4.3.3. Service benchmarking
                            8.4.3.4. Strategic initiatives
                        8.4.4. Koninklijke Philips N.V.
                            8.4.4.1. Company overview
                            8.4.4.2. Financial performance
                            8.4.4.3. Service benchmarking
                            8.4.4.4. Strategic initiatives
                        8.4.5. Canon Medical Systems
                            8.4.5.1. Company overview
                            8.4.5.2. Financial performance
                            8.4.5.3. Service benchmarking
                            8.4.5.4. Strategic initiatives
                        8.4.6. F. Hoffmann-La Roche Ltd
                            8.4.6.1. Company overview
                            8.4.6.2. Financial performance
                            8.4.6.3. Service benchmarking
                            8.4.6.4. Strategic initiatives
                        8.4.7. Illumina, Inc.
                            8.4.7.1. Company overview
                            8.4.7.2. Financial performance
                            8.4.7.3. Service benchmarking
                            8.4.7.4. Strategic initiatives
                        8.4.8. Guardant Health, Inc.
                            8.4.8.1. Company overview
                            8.4.8.2. Financial performance
                            8.4.8.3. Service benchmarking
                            8.4.8.4. Strategic initiatives
                        8.4.9. Thermo Fisher Scientific Inc.
                            8.4.9.1. Company overview
                            8.4.9.2. Financial performance
                            8.4.9.3. Service benchmarking
                            8.4.9.4. Strategic initiatives
                        8.4.10. FONAR Corporation
                            8.4.10.1. Financial performance
                            8.4.10.2. Service benchmarking
                            8.4.10.3. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. non-invasive cancer diagnostic market, by product, 2021 - 2033 (USD Million)
Table 3 U.S. non-invasive cancer diagnostic market, by technology, 2021 - 2033 (USD Million)
Table 4 U.S. non-invasive cancer diagnostic market, by indication, 2021 - 2033 (USD Million)
Table 5 U.S. non-invasive cancer diagnostic market, by end user, 2021 - 2033 (USD Million)
Table 6 Financial performance
Table 7 Key companies undergoing expansions
Table 8 Key companies undergoing acquisitions
Table 9 Key companies undergoing collaborations
Table 10 Key companies launching new products/services
Table 11 Key companies undergoing partnerships
Table 12 Key companies undertaking other strategies

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. non-invasive cancer diagnostic market: market outlook
Fig. 10 U.S. non-invasive cancer diagnostic market competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. non-invasive cancer diagnostic market driver impact
Fig. 16 U.S. non-invasive cancer diagnostic market restraint impact
Fig. 17 U.S. non-invasive cancer diagnostic market strategic initiatives analysis
Fig. 18 U.S. non-invasive cancer diagnostic market: product movement analysis
Fig. 19 U.S. non-invasive cancer diagnostic market: product outlook and key takeaways
Fig. 20 Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 Pathology-based instruments market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Polymerase Chain Reaction (PCR) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Next-generation Sequencing (NGS) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Microarrays market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Imaging instruments market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Computed Tomography (CT) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Positron Emission Tomography (PET) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Mammography market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Others (Ultrasound, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 U.S. non-invasive cancer diagnostic market: by technology, movement analysis
Fig. 34 U.S. non-invasive cancer diagnostic market: technology outlook and key takeaways
Fig. 35 Imaging market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Liquid biopsy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 U.S. non-invasive cancer diagnostic market: by indication, movement analysis
Fig. 39 U.S. non-invasive cancer diagnostic market: indication outlook and key takeaways
Fig. 40 Lung cancer market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Breast cancer market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Colorectal cancer market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Prostate market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Liver market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 Cervical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Skin market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Others (Thyroid Cancer, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 U.S. non-invasive cancer diagnostic market: by end user, movement analysis
Fig. 50 U.S. non-invasive cancer diagnostic market: end user outlook and key takeaways
Fig. 51 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 53 Others (Academic & Research Institutes, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)